Your session is about to expire
← Back to Search
Acupressure for Rheumatoid Arthritis
N/A
Waitlist Available
Led By Anne Murphy, MD
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 42
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to see if acupressure, a method of applying pressure to specific body points, is practical and comfortable for people with rheumatoid arthritis, a painful joint condition.
Eligible Conditions
- Rheumatoid Arthritis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to day 42
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 42
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Acceptability of Self-performed Acupressure in Patients With RA Assessed by Acupressure Tolerability Scale at Day 42 - Question 1
Acceptability of Self-performed Acupressure in Patients With RA Assessed by Acupressure Tolerability Scale at Day 42 - Question 2
Acceptability of Self-performed Acupressure in Patients With RA Assessed by Acupressure Tolerability Scale at Day 42 - Question 3
+2 moreSecondary study objectives
Change in Fibromyalgia Survey Questionnaire
Change in the Patient-Reported Outcomes Measurement Information System Adult Profile (PROMIS-29 +2) - Anxiety
Change in the Patient-Reported Outcomes Measurement Information System Adult Profile (PROMIS-29 +2) - Cognitive Function
+6 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: AcupressureExperimental Treatment1 Intervention
The self-acupressure intervention will be delivered using the modified MeTime Acupressure mobile application (App) in addition to in-person or virtual instruction via study staff.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acupressure
2016
N/A
~1530
Find a Location
Who is running the clinical trial?
University of MichiganLead Sponsor
1,849 Previous Clinical Trials
6,431,506 Total Patients Enrolled
3 Trials studying Rheumatoid Arthritis
606 Patients Enrolled for Rheumatoid Arthritis
Anne Murphy, MDPrincipal InvestigatorUniversity of Michigan
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are taking the medication called Leflunomide (brand name Arava).You have difficulty seeing or hearing that would make it hard for you to take part in the study.You have a serious mental health condition or a history of substance abuse problems.You are taking hydroxychloroquine (Plaquenil).You are currently taking a medication called baricitinib (brand name Olumiant).You are taking very strong pain medications, such as opioids, in high doses (more than 100 oral morphine equivalents).You are currently taking a medication called sulfasalazine (brand name Azulfadine).You are currently taking a medication called abatacept (Orencia).You have an allergy or known sensitivity to the medication tocilizumab (brand name Actemra).You are currently taking a medication called tumor necrosis factor inhibitor (TNFi).You are taking Etanercept (Enbrel) medication.You are taking a medication called a Janus kinase inhibitor (JAKi).You are taking a medication called tofacitinib (Xeljanz).You are taking the medication called Upadacitinib (Rinvoq).
Research Study Groups:
This trial has the following groups:- Group 1: Acupressure
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger